Roche and Biogen Idec report positive result for suspended RA study
This article was originally published in Scrip
Executive Summary
Roche and Biogen Idec's recently-halted Phase III SCRIPT trial of the anti-CD20 humanised monoclonal antibody ocrelizumab improved the signs and symptoms of rheumatoid arthritis in patients with a previous inadequate response to at least one anti-tumour necrosis factor (TNF)-alpha therapy, show top-line data.